ArticleCancer medicine2026
Association of the Affordable Care Act With Receipt of Guideline-Concordant Adjuvant Chemotherapy for Colon and Non-Small Cell Lung Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccess to high-quality care, defined as receipt of guideline-concordant treatment, is crucial for cancer outcomes, and insurance coverage is an important determinant of such care. This study investigated the association between the Affordable Care Act (ACA), which expanded insurance coverage, and receipt of guideline-concordant adjuvant chemotherapy for non-small cell lung cancer (NSCLC) and colon cancer.
methodsOur retrospective study includes data from Pennsylvania Cancer Registry for patients aged 26-64 with Stage 3 colon cancer or Stage IIB/Stage IIIA/Stage IIIB NSCLC between 2010-2019. Based on review of literature and National Comprehensive Cancer Network guidelines, we focused on receipt of adjuvant chemotherapy as our measure of guideline-concordant care. We employed interrupted time series analysis to assess changes in level and annual trend of receipt of adjuvant chemotherapy following ACA implementation. Analyses were performed overall and by subgroups defined by race/ethnicity, rurality, and ADI quartile.
resultsAcross the study period, 83.9% of colon cancer and 61.7% of NSCLC patients received chemotherapy after surgery. Post-ACA, we observed a non-significant increase in annual rate (slope change) of post-operative colon cancer patients receiving guideline-concordant chemotherapy (+0.74 percentage points per year (pppy), p = 0.68), with larger, non-significant increases among non-White patients (+7.73 pppy, p = 0.16), rural residents (+9.74 pppy, p = 0.05), and those from ADI Q4 (high deprivation) neighborhoods (+3.92 pppy, p = 0.24). For NSCLC, there was a non-significant decrease in annual rate of receipt of guideline-concordant chemotherapy (-1.34 pppy, p = 0.30).
conclusionsThere were no statistically significant trends in our primary models. Estimates suggest potential increases in receipt of guideline-concordant chemotherapy for post-operative colon cancer patients post-ACA, overall and among underserved groups, and potential decreases in receipt of guideline-concordant chemotherapy for NSCLC patients post-ACA, overall and among underserved groups. These findings warrant further study of linkages between comprehensive insurance coverage and disparities in colon cancer and NSCLC care and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.